IE
AMPE

Israel Englander’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

Israel Englander’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-354
Closed -$432K – 4213
2017
Q4 		$432K Buy
+354
New +$166K ﹤0.01% 3168

Other funds holding AMPE

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $3.06B AUM 26.31% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Israel Englander's AMPE Position: Q2 2023 in Review

Israel Englander sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q2 2023, closing a stake of 2,008 shares — an estimated $9K sold.

Israel Englander first reported a position in AMPE in Q1 2014 and held it in 23 quarters. The position peaked at $3.23M in Q1 2021. 34 funds tracked by Wall St. Rank hold AMPE as of Q2 2023.

  • Israel Englander reported no remaining Ampio Pharmaceuticals Inc. position as of Q2 2023 after selling out during the quarter.
  • Israel Englander sold 2,008 Ampio Pharmaceuticals Inc. shares in Q2 2023, an estimated $9K.
  • Israel Englander first reported a position in Ampio Pharmaceuticals Inc. in Q1 2014 and held it in 23 quarters.
  • Israel Englander's Ampio Pharmaceuticals Inc. position peaked at $3.23M in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.